Compare Ginkgo Bioworks Holdings Inc (DNA) vs Okta, Inc. (OKTA) Price & Performance

Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.

DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.

OKTA trades at $150.77, up 1.65% today, with a bullish technical signal from moving averages and strong quarterly earnings beats. Revenue grew to $2.61B in 2025, achieving a net income of $28M after recent losses. The company maintains a 77.44% gross margin and positive operating cash flow of $750M, supported by strategic acquisitions like Permiso Security for AI threat defense.

Outlook remains positive with 72.55% analyst buy ratings and a consensus price target of $129.71, though high valuation ratios (P/E 108.93) and overbought RSI levels near 76.86 pose risks. Key catalysts include Q2 2026 earnings on August 26, 2026, and growth in cybersecurity demand.